Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 12, Number 9—September 2006

Research

Multidrug-resistant Tuberculosis Management in Resource-limited Settings

Eva Nathanson*Comments to Author , Catharina Lambregts-van Weezenbeek†, Michael Rich‡, Rajesh Gupta*, Jaime Bayona‡§, Kai Blöndal†, José A. Caminero¶, J. Peter Cegielski#, Manfred Danilovits**, Marcos A. Espinal*, Vahur Hollo††, Ernesto Jaramillo*, Vaira Leimane‡‡, Carole D. Mitnick§§, Joia S. Mukherjee§§, Paul Nunn*, Alexander Pasechnikov‡¶¶, Thelma E. Tupasi##, Charles Wells#, and Mario C. Raviglione*
Author affiliations: *World Health Organization, Geneva, Switzerland; †KNCV Tuberculosis Foundation, The Hague, the Netherlands; ‡Partners In Health, Boston, Massachusetts, USA; §Socios En Salud, Lima, Peru; ¶International Union Against Tuberculosis and Lung Disease, Paris, France; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Tartu University Clinics, Tartu, Estonia; ††National TB Programme, Tallinn, Estonia; ‡‡State Centre of Tuberculosis and Lung Diseases of Latvia, Riga, Latvia; §§Harvard Medical School, Boston, Massachusetts, USA; ¶¶MDR-TB Project in Tomsk Oblast, Tomsk, Russian Federation; ##Makati Medical Center, Makati, the Philippines

Main Article

Table 5

Treatment outcomes of new, previously treated, and all multidrug-resistant tuberculosis patients

Patients
 Estonia, n (%)
 Latvia, n (%)
 Lima, n (%)
 Manila, n (%)
 Tomsk, n (%)
 Total, n (%)
New patients
Cured 16 (72.7) 72 (79.1) 0 1 (20.0) 0 89 (74.8)
Completed 1 (4.5) 1 (1.1) 0 1 (20.0) 0 3 (2.5)
Default 3 (13.6) 13 (14.3) 0 2 (40.0) 0 18 (15.1)
Failed 1 (4.5) 4 (4.4) 0 0 0 5 (4.2)
Died 1 (4.5) 1 (1.1) 1 (100.0) 1 (20.0) 0 4 (3.4)
Transferred 0 0 0 0 0 0
Total 22 (100.0) 91 (100.0) 1 (100.0) 5 (100.0) 0 119 (100.0)
Treatment success 17 (77.3) 73 (80.2) 0 2 (40.0) 0 92 (77.3)
Previously treated patients
Cured 12 (50.0) 93 (60.4) 351 (69.2) 60 (60.0) 118 (82.5) 634 (68.3)
Completed 1 (4.2) 2 (1.3) 0 0 0 3 (0.3)
Default 4 (16.7) 27 (17.5) 40 (7.9) 12 (12.0) 9 (6.3) 92 (9.9)
Failed 3 (12.5) 24 (15.6) 17 (3.4) 12 (12.0) 9 (6.3) 65 (7.0)
Died 4 (16.7) 8 (5.2) 98 (19.3) 15 (15.0) 7 (4.9) 132 (14.2)
Transferred 0 0 1 (0.2) 1 (1.0) 0 2 (0.2)
Total 24 (100.0) 154 (100.0) 507 (100.0) 100 (100.0) 143 (100.0) 928 (100.0)
Treatment success 13 (54.2) 95 (61.7) 351 (69.2) 60 (60.0) 118 (82.5) 637 (68.6)
All patients
Cured 28 (60.9) 165 (67.3) 351 (69.1) 61 (58.2) 118 (82.5) 723 (69.1)
Completed 2 (4.3) 3 (1.2) 0 1 (1.0) 0 6 (0.6)
Default 7 (15.2) 40 (16.3) 40 (7.9) 14 (13.3) 9 (6.3) 110 (10.5)
Failed 4 (8.6) 28 (11.4) 17 (3.3) 12 (11.4) 9 (6.3) 70 (6.7)
Died 5 (10.9) 9 (3.7) 99 (19.5) 16 (15.2) 7 (4.9) 136 (13.0)
Transferred 0 0 1 (0.2) 1 (1.0) 0 2 (0.2)
Total 46 (100.0) 245 (100.0) 508 (100.0) 105 (100.0) 143 (100.0) 1047 (100.0)
Treatment success 30 (65.2) 168 (68.6) 351 (69.1) 62 (59.0) 118 (82.5) 729 (69.6)

Main Article

Page created: November 17, 2011
Page updated: November 17, 2011
Page reviewed: November 17, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external